Article By:
Jason Napodano
Monday, December 12, 2016 11:33 AM EDT
ImMucin is expected to qualify as an Orphan Drug in the U.S., which will provide certain cost and time advantages to development, as well as market exclusivity one approved. I expect the company to move into Phase 2 in 2017.
In this article: VXLLF